The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology AmorphOX®. Abera is a developer of mucosal vaccines and has several preclinical vaccine candidates based on Abera's innovative vaccine platform. The AmorphOX technology has...
Read More Details
Finally We wish PressBee provided you with enough information of ( Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology )
Also on site :
- Ben & Jerry's New Ice Cream Flavor Has Fans Saying the Same Thing
- Iconic '70s Rocker Releases First Album In Nearly a Decade
- 2 healthcare workers accused of elder abuse after woman, 92, found with broken bones